Back

Physicians’ Education Resource

  • Castration
  • Positron-Emission Tomography
  • Prostatic Neoplasms

Cases and Conversations(TM): Integrating PSMA-Directed Radioligand Therapy in Prostate Cancer Care: Recent Data and Evolving Strategies

Prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains a leading cause of cancer-related morbidity and mortality. Although PSMA PET imaging and PSMA-directed radioligand therapy (RLT) have improved diagnostic and treatment options, clinicians continue to face gaps in knowledge related to patient selection, sequencing, toxicity management, and equitable access to these evolving therapies This case-based, interactive program is designed to enhance clinician competence and support evidence-based integration of PSMA-directed imaging and RLT into prostate cancer care. This educational activity is an archive of the live virtual symposium held on April 1, 2026.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME · seen on gotoper.com

  • Case-based learning
  • Credit · Up to 1.5 credits
  • Commercial Support
  • Released
    Apr 16, 2026
  • Last day to claim credit
    Apr 17, 2027 6 months left